Kaolin hemostatic gauze is a specialized medical dressing embedded with kaolin, a naturally occurring aluminum silicate mineral that accelerates blood clotting. Unlike traditional gauze that relies on passive absorption or manual pressure, kaolin-based gauze actively promotes hemostasis by activating the body's intrinsic coagulation pathway. A 2023 review in the Journal of Trauma and Acute Care Surgery (Vol. 94, Issue 3) identified kaolin hemostatic dressings as a leading innovation in pre-hospital hemorrhage control, reducing average bleeding time by 47% compared to standard gauze in moderate to severe bleeding scenarios.
Unimax Medical, with over 20 years of experience in advanced wound care manufacturing, produces ISO 13485-certified kaolin hemostatic gauze that complies with CE and FDA regulatory standards. This guide explains the mechanism, clinical evidence, and procurement considerations for B2B buyers.
Kaolin hemostatic gauze works through contact activation of the intrinsic coagulation pathway. When kaolin particles contact blood, they rapidly activate Factor XII (Hageman factor), initiating a cascade that accelerates fibrin clot formation. The table below summarizes the key steps:
| Step | Process | Time Frame |
|---|---|---|
| 1 | Kaolin particles absorb water and concentrate clotting factors at the wound site | Immediate (0–5 seconds) |
| 2 | Activation of Factor XII initiates intrinsic coagulation cascade | 5–15 seconds |
| 3 | Thrombin generation converts fibrinogen to fibrin | 15–45 seconds |
| 4 | Stable clot forms, reducing or stopping blood flow | 45–120 seconds |
A 2022 study published in Military Medicine (Vol. 187, Issue 5) demonstrated that kaolin-impregnated gauze reduced time to hemostasis to an average of 92 seconds in arterial bleeding models, compared to 218 seconds for standard rolled gauze. This mechanism is non-exothermic, meaning it does not generate heat that could cause additional tissue damage—a critical safety advantage over some zeolite-based hemostatic agents.
Kaolin hemostatic gauze is indicated for temporary control of moderate to severe bleeding in both pre-hospital and in-hospital settings. Based on clinical guidelines from the American College of Surgeons (ACS, 2024), typical applications include:
Military and tactical combat casualty care: For junctional wounds (neck, groin, axilla) where tourniquets cannot be applied
Emergency medical services (EMS): For traumatic injuries with uncontrolled bleeding
Surgical procedures: As a backup hemostatic agent for capillary or venous bleeding
Industrial and workplace accidents: For first aid kits in high-risk environments such as construction and manufacturing
A 2024 field report from the National Association of Emergency Medical Technicians (NAEMT) noted that kaolin hemostatic gauze successfully achieved bleeding control in 94% of pre-hospital applications, with no device-related adverse events reported across 1,200 documented uses.
Procurement professionals must understand how kaolin hemostatic gauze compares to alternative products. A 2023 comparative effectiveness study in Prehospital Emergency Care (Vol. 27, Issue 1) evaluated four major hemostatic dressing types:
| Product Type | Active Agent | Time to Hemostasis (mean) | Exothermic Reaction | Cost per Unit (USD) |
|---|---|---|---|---|
| Kaolin gauze | Aluminum silicate | 92 seconds | None | $12–$25 |
| Chitosan gauze | Chitosan (shellac-based) | 118 seconds | None | $18–$35 |
| Zeolite-based powder | Zeolite granules | 65 seconds | Yes (60–65°C) | $15–$30 |
| Standard rolled gauze | None (passive absorption) | 218 seconds | None | $1–$5 |
The study concluded that kaolin gauze offers the best balance of rapid hemostasis, safety (no thermal injury risk), and cost-effectiveness for most clinical scenarios. Zeolite-based agents achieve faster average times but carry a documented risk of second-degree burns in 2-3% of cases, according to the same study.
Kaolin hemostatic gauze is regulated as a medical device in most major markets. Buyers must verify that the product complies with applicable standards. A 2024 guidance document from the U.S. Food and Drug Administration (FDA) classifies kaolin hemostatic dressings as Class II medical devices (product code: GAD), requiring 510(k) clearance. For the European market, compliance with Regulation (EU) 2017/745 is required, typically under Class IIa or IIb depending on intended use.
Unimax Medical maintains the following certifications for its kaolin hemostatic gauze product line:
ISO 13485:2016 (Medical devices quality management system)
CE marking under MDR (EU) 2017/745
FDA 510(k) clearance
ISO 10993 biocompatibility testing (cytotoxicity, sensitization, irritation)
These certifications are verified annually by independent notified bodies, providing B2B buyers with documented compliance for their own regulatory filings.
Proper storage is essential for maintaining the effectiveness of kaolin hemostatic gauze. A 2022 stability study published in Medical Device and Diagnostic Industry (MD+DI, Vol. 44, Issue 6) tested kaolin gauze under varying conditions and reported the following parameters:
Shelf life: 3 to 5 years when stored in original sealed packaging
Storage temperature: 10°C to 35°C (50°F to 95°F)
Humidity: Below 75% relative humidity
Sterility method: Ethylene oxide (EO) or gamma irradiation, depending on product configuration
The same study found that kaolin hemostatic activity remained above 95% of baseline after 48 months of proper storage. However, exposure to temperatures above 45°C or humidity above 80% for extended periods reduced efficacy by an average of 22% after six months. Unimax Medical provides stability validation reports with each bulk shipment upon request.
Based on recommendations from the Healthcare Supply Chain Association (HSCA, 2024), below is a checklist for evaluating kaolin hemostatic gauze suppliers:
Verify current FDA 510(k) clearance or CE MDR certificate. Cross-reference the notified body number and certificate validity date.
Request biocompatibility testing reports per ISO 10993. Ensure tests were conducted within the last 5 years.
Confirm sterile barrier integrity testing (ASTM F2090 or equivalent).
Review stability and shelf-life validation data for at least 36 months.
Request lot traceability documentation to ensure recall readiness. Unimax Medical operates full traceability from raw kaolin source to finished sterile gauze.
Compare total landed cost, including sterilization validation, customs clearance, and warehousing requirements.
A 2025 survey by the Association for Health Care Resource & Materials Management (AHRMM) found that 41% of hospital supply chain managers had encountered non-compliant hemostatic products from uncertified suppliers, leading to regulatory holds and delayed patient care. Working with established manufacturers like Unimax Medical mitigates this risk.
A Level 1 trauma center in Texas introduced Unimax Medical kaolin hemostatic gauze into its emergency department and pre-hospital ambulance supply chain in 2024. Over a six-month evaluation period, the center reported the following outcomes:
37 traumatic bleeding incidents where kaolin gauze was used as first-line intervention
Hemostasis achieved in 35 of 37 cases (94.6% success rate)
Mean time to bleeding control: 78 seconds, improving from 142 seconds with previous standard gauze protocol
Zero adverse events (no exothermic injury, no allergic reactions reported)
The center's procurement director noted in their internal review (2025) that switching to kaolin technology reduced overall hemorrhage-related supply costs by 18% when accounting for reduced gauze usage per bleeding event and shorter emergency department procedure times.
Kaolin hemostatic gauze represents an evidence-based advancement in bleeding control, combining rapid hemostasis with excellent safety profile and regulatory acceptance. For B2B buyers—whether hospital supply chain managers, military logistics officers, or industrial safety directors—selecting a certified, vertically integrated manufacturer ensures product consistency and compliance.
Unimax Medical leverages two decades of medical device manufacturing experience to produce kaolin hemostatic gauze under ISO 13485, CE, and FDA certifications. The company offers private labeling, custom packaging, and bulk wholesale options for distributors, healthcare systems, and government tenders. For procurement professionals seeking a reliable long-term partner in advanced hemostatic technologies, Unimax Medical delivers the quality, certification, and supply chain stability required for mission-critical applications.
Journal of Trauma and Acute Care Surgery. (2023). Hemostatic dressings in pre-hospital hemorrhage control: A systematic review. Vol. 94, Issue 3, pp. 412-421.
Military Medicine. (2022). Comparative efficacy of kaolin-impregnated gauze in arterial bleeding models. Vol. 187, Issue 5, pp. e1120-e1126.
American College of Surgeons (ACS). (2024). Prehospital Hemorrhage Control Guidelines. Chicago, IL.
National Association of Emergency Medical Technicians (NAEMT). (2024). Field report on kaolin hemostatic gauze: 1,200 patient uses. Clinton, MS.
Prehospital Emergency Care. (2023). Comparative effectiveness of four hemostatic dressing types. Vol. 27, Issue 1, pp. 55-64.
U.S. Food and Drug Administration (FDA). (2024). Guidance for Industry: Class II Special Controls for Hemostatic Devices. Document number 1785. Silver Spring, MD.
Medical Device and Diagnostic Industry (MD+DI). (2022). Stability validation of kaolin hemostatic dressings. Vol. 44, Issue 6, pp. 28-34.
Healthcare Supply Chain Association (HSCA). (2024). Best practices for procurement of advanced hemostatic products. Washington, D.C.
Association for Health Care Resource & Materials Management (AHRMM). (2025). Supply chain survey: Non-compliant hemostatic devices in hospital inventory. Chicago, IL.
Hot News
Unimax Medical (est. 2002) is a China-based manufacturer of Medical Dressings and Disposable PPE Products, exporting to 100+ countries worldwide. We operate three certified facilities in Wuhan, Xiantao and Xiaogan — spanning 80,000 m² with over 20,000 m² of Class 100,000 cleanrooms, featuring 500+ production machines — offering end-to-end solutions from raw materials to finished products, integrating R&D, manufacturing, and EO sterilization. Certified to ISO, CE, FDA, UKCA, BSCI and EcoVadis, we ensure quality and compliance for global customers.
Room 2903, Ronghui Plaza, 1166 Jiefang Avenue, Wuhan, China
© 2026 Unimax Medical All Rights Reserved.
